Incorporating HIV/HCV Prevention, Screening, and Linkage to Care Into Opioid Use Disorder Treatment Settings

In this downloadable slideset, CCO’s expert faculty reviews important strategies for expanding addiction medicine services to include prevention, screening, diagnosis, and linkage to HCV and HIV care for patients with opioid use disorder.
Alain H. Litwin, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.42 MB
Released: September 18, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
American Society of Addiction Medicine
Educational grant provided by:
Gilead Sciences

Related Content

Concise Clinical Care Options (CCO) presentation by Colleen Kelley, MD, MPH, on investigational long-acting HIV PrEP regimens in late stages of clinical development

Colleen Kelley, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: September 20, 2021 Expired: September 19, 2022

CCO slides from Dr. Colleen Kelley, on investigational long-acting HIV PrEP regimens in late stages of clinical development

Colleen Kelley, MD, MPH Released: September 20, 2021

Clinical Care Options (CCO) faculty Dr David Malebranche’s expert commentary on racial disparities in HIV care and strategies for improving patient engagement

David Malebranche, MD, MPH Released: September 15, 2021

Dr Milena Murray and Clinical Care Options (CCO): Current pharmacokinetic and safety data support the use of tenofovir alafenamide during pregnancy

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue